Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders

Madhusudan Grover, Spencer D. Dorn, Stephan R. Weinland, Christine B. Dalton, Bradley N. Gaynes, Douglas A. Drossman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.

Original languageEnglish (US)
Pages (from-to)1284-1291
Number of pages8
JournalDigestive Diseases and Sciences
Volume54
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Gastrointestinal Diseases
Antipsychotic Agents
Antidepressive Agents
Therapeutics
Analgesics
Sleep
Outpatients
Anxiety
Interviews
Psychology
Quetiapine Fumarate

Keywords

  • Antidepressants
  • Atypical antipsychotics
  • Functional gastrointestinal disorders
  • Irritable bowel syndrome
  • Psychotropic agents
  • Quetiapine
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. / Grover, Madhusudan; Dorn, Spencer D.; Weinland, Stephan R.; Dalton, Christine B.; Gaynes, Bradley N.; Drossman, Douglas A.

In: Digestive Diseases and Sciences, Vol. 54, No. 6, 06.2009, p. 1284-1291.

Research output: Contribution to journalArticle

Grover, Madhusudan ; Dorn, Spencer D. ; Weinland, Stephan R. ; Dalton, Christine B. ; Gaynes, Bradley N. ; Drossman, Douglas A. / Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. In: Digestive Diseases and Sciences. 2009 ; Vol. 54, No. 6. pp. 1284-1291.
@article{a5ad099e0ade4aaf93fde4dc6c7b6f4b,
title = "Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders",
abstract = "Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.",
keywords = "Antidepressants, Atypical antipsychotics, Functional gastrointestinal disorders, Irritable bowel syndrome, Psychotropic agents, Quetiapine, Treatment",
author = "Madhusudan Grover and Dorn, {Spencer D.} and Weinland, {Stephan R.} and Dalton, {Christine B.} and Gaynes, {Bradley N.} and Drossman, {Douglas A.}",
year = "2009",
month = "6",
doi = "10.1007/s10620-009-0723-6",
language = "English (US)",
volume = "54",
pages = "1284--1291",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders

AU - Grover, Madhusudan

AU - Dorn, Spencer D.

AU - Weinland, Stephan R.

AU - Dalton, Christine B.

AU - Gaynes, Bradley N.

AU - Drossman, Douglas A.

PY - 2009/6

Y1 - 2009/6

N2 - Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.

AB - Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.

KW - Antidepressants

KW - Atypical antipsychotics

KW - Functional gastrointestinal disorders

KW - Irritable bowel syndrome

KW - Psychotropic agents

KW - Quetiapine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67349132474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349132474&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-0723-6

DO - 10.1007/s10620-009-0723-6

M3 - Article

C2 - 19242800

AN - SCOPUS:67349132474

VL - 54

SP - 1284

EP - 1291

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 6

ER -